Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Relapse Prevention in Major Depressive Disorder
NCT00036309Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Duloxetine Arm with Placebo Arm (2 arms). Primary endpoint: Time to Relapse of Major Depressive Disorder at 26 weeks. Started May 2002; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00036309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036309.